Jasper Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held by Jasper Therapeutics, Inc. on July 3, 2025. The meeting was conducted virtually or by proxy, with approximately 80% of the 15,022,122 shares issued and outstanding as of the May 9, 2025 record date represented.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on four proposals, all of which were approved:
- Proposal 1 (Director Election): Three Class I directors were elected to serve until the 2028 annual meeting.
- Kurt von Emster: 8,467,774 votes for.
- Scott Brun, M.D.: 8,612,491 votes for.
- Vishal Kapoor: 8,567,506 votes for.
- Proposal 2 (Auditor Ratification): PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 11,992,658 votes for.
- Proposal 3 (Executive Compensation): The compensation of named executive officers was approved on an advisory basis with 8,108,299 votes for.
- Proposal 4 (Say-on-Pay Frequency): Stockholders voted to hold future advisory votes on executive compensation every one year (8,580,886 votes for).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, specific risks, or contingencies. The Company has determined to hold future advisory votes on executive compensation on an annual basis based on the stockholder vote.
Key Facts for Investor Verification
- Verify the definitive proxy statement filed on May 19, 2025, for detailed background on the director nominees and executive compensation.
- Confirm the total number of shares outstanding and the record date (May 9, 2025) to validate the 80% participation rate.
- Note that PricewaterhouseCoopers LLP is the appointed auditor for the fiscal year ending December 31, 2025.
- Future executive compensation advisory votes will occur annually.